Evidence map›Paper›PMID 41456240›Full record

ArticleInternational journal of hematology2026

Measurable residual disease after venetoclax treatment for relapsed or refractory chronic lymphocytic leukemia in Japan.

Hirotaka Matsui, Jun Takizawa, Kensuke Kojima, Tetsuzo Tauchi, Chiaki Ikeda, Yu Aruga, Hiroki Sakamoto, Risa Takenaka, Jinhaeng Park, Tetsuo Morita and 2 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Hirotaka MatsuiDepartment of Laboratory Medicine, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, Japan. hmatsui@ncc.go.jp.ORCID http://orcid.org/0000-0002-6266-3227
Jun TakizawaFaculty of Medicine, Niigata University, Niigata, Japan.
Kensuke KojimaDepartment of Hematology, Kochi Medical School, Kochi University, Kochi, Japan.
Tetsuzo TauchiShin-Yurigaoka General Hospital, Kanagawa, Japan.
Chiaki IkedaDepartment of Laboratory Medicine, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, Japan.
Yu ArugaDepartment of Laboratory Medicine, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, Japan.
Hiroki SakamotoSapporo Clinical Laboratory Inc., Hokkaido, Japan.
Risa TakenakaAbbVie GK, Tokyo, Japan.
Jinhaeng ParkAbbVie GK, Tokyo, Japan.
Tetsuo MoritaAbbVie GK, Tokyo, Japan.
Hiromichi MatsushitaDepartment of Laboratory Medicine, Keio University School of Medicine, Tokyo, Japan.
Ritsuro SuzukiFaculty of Medicine, Shimane University, Shimane, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Measurable residual disease (MRD), defined as the persistence of minimal levels of leukemic cells following therapeutic intervention, serves as a pivotal prognostic biomarker in patients with chronic lymphocytic leukemia (CLL). We conducted a multicenter, cross-sectional study to assess MRD in Japanese patients with relapsed or refractory CLL. All patients received venetoclax-based therapy for 24 months. MRD in peripheral blood (PB) and bone marrow was assessed by multicolor flow cytometry using surface markers, including kappa and lambda light chains of surface immunoglobulins. The primary and secondary outcomes were the proportions of patients who achieved undetectable MRD (uMRD, < 10

Indexed as

Antineoplastic AgentsBridged Bicyclo Compounds, HeterocyclicLeukemia, Lymphocytic, Chronic, B-CellSulfonamidesAgedAged, 80 and overCross-Sectional StudiesFemaleFlow CytometryHumansJapanMaleMiddle AgedNeoplasm, ResidualPrognosisRecurrenceAntineoplastic AgentsBridged Bicyclo Compounds, HeterocyclicSulfonamidesvenetoclaxChronic lymphocytic leukemiaMeasurable residual diseaseReal worldVenetoclax

Identifiers

PMID41456240
PMCPMC13171686

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.